Affordable Access

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme.

Authors
  • Fazeny-Dörner, B1
  • Veitl, M
  • Wenzel, C
  • Rössler, K
  • Ungersböck, K
  • Dieckmann, K
  • Piribauer, M
  • Hainfellner, J
  • Marosi, C
  • 1 Clinical Division of Oncology and Ludwig Boltzmann Institute for Clinical and Experimental Oncology, Department of Internal Medicine I, University of Vienna, Austria. [email protected] , (Austria)
Type
Published Article
Journal
British journal of cancer
Publication Date
Feb 24, 2003
Volume
88
Issue
4
Pages
496–501
Identifiers
PMID: 12592361
Source
Medline
License
Unknown

Abstract

A total of 55 patients with histologically proven glioblastoma multiforme (total gross resection: n=24, subtotal resection: n=20, stereotactic biopsy: n=11) were treated with the combination of dacarbazine (D) (200 mg m(-2)) and fotemustine (F) (100 mg m(-2)) and concomitant radiotherapy (2 Gy day(-1), 5 days per week using limited fields up to 60 Gy) to assess efficacy and toxicity of this regimen. Survival (median survival, 12-, 18- and 24-month survival rates) and time to progression (median time to progression (TTP), 6-month progression-free survival) were analysed by Kaplan-Meier's method. A total of 268 (range 1-8, median: 5) cycles were administered. Median survival is 14.5+ (range: 0.5-40+) months, and the 12-, 18- and 24-month survival rates are 58, 29 and 23%, respectively. Median TTP from the start of D/F therapy is 9.5+ (range: 0.5-33+) months. The 6-month progression-free survival is 54%. Partial remissions were observed in 3.6%. Main toxicity was thrombocytopenia. Five patients were excluded from further D/F application, four patients because of prolonged thrombocytopenia NCI-CTC grades 3 and 4 and one patient because of whole body erythrodermia. One patient died because of septic fever during thrombocytopenia and leukopenia NCI-CTC grade 4 after the first cycle. No other toxicities of NCI-CTC grade 3 or 4 occurred. The treatment is feasible in a complete outpatient setting and the results of the D/F regimen justify further investigations with these compounds.

Report this publication

Statistics

Seen <100 times